Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.

Naoya IkedaRyo AraiSayo SodaTakashi InoueNobuhiko UchidaYusuke NakamuraMeitetsu MasawaYoshitomo KushimaHiroaki OkutomiAkihiro TakemasaYasuo ShimizuSeiji Niho

Published in: Thoracic cancer (2022)

Combination chemotherapy with carboplatin plus nab-paclitaxel for recurrent SCLC had a modest activity, although the primary study endpoint was not met. Further investigation of this regimen for patients with recurrent SCLC and interstitial pneumonia is warranted.

Keyphrases

phase ii study
locally advanced
small cell lung cancer
open label
rectal cancer
advanced non small cell lung cancer
placebo controlled
chemotherapy induced
clinical trial
randomized controlled trial
phase iii
intensive care unit